Literature DB >> 9234571

Silent thalassemias: genotypes and phenotypes.

I Bianco1, M P Cappabianca, E Foglietta, M Lerone, G Deidda, L Morlupi, P Grisanti, D Ponzini, S Rinaldi, B Graziani.   

Abstract

BACKGROUND AND
OBJECTIVE: Current application of molecular biology techniques to the study of the DNA of globin genes has confirmed the existence of silent alpha and beta thalassemias; which had already been reported on the basis of red blood cell parameters and family studies. The present work was aimed at analyzing all the aspects of the phenotype of the most common varieties of silent thalassemia.
MATERIALS AND METHODS: Groups of heterozygous carriers of these varieties were examined using established techniques that determined all hematologic, hemoglobin (electrophoresis and measurement of Hb A2 and Hb F levels), and globin synthesis (evaluation of the alpha/beta ratio) parameters. Furthermore, all subjects underwent a complete molecular study of the alpha and beta globin genes by means of the ARMS, SSCP, DGGE, PCR and Southern blotting techniques.
RESULTS: 1) The -101 C-->T mutation of the promoter of the beta globin gene shows a normal hematological picture with the Hb A2 level often slightly raised and the alpha/beta globin synthesis ratio slightly greater than 1; 2) beta + thalassemia resulting from the IVS II 844 C-->G mutation has a phenotype that is even closer to normal; 3) -alpha 3.7 deletion type I usually has a totally silent phenotype; 4) the alpha Ncol mutation almost always gives rise to a sub-silent phenotype if it is located on gene alpha 2 and to a silent phenotype if it is found on gene alpha 1; 5) alpha + thalassemia due to the alpha 2 Hphl mutation displays a sub-silent phenotype in some cases and a silent one in others; 6) triplication of the alpha genes gives rise to a phenotype that is quite similar to that of the -101 C-->T mutation of the promoter of the beta globin gene, namely one that is very often silent. INTERPRETATION AND
CONCLUSIONS: Many of these silent varieties (beta + thalassemia due to the -101 C-->T mutation; alpha + thalassemia from a deletion or point mutation of an alpha gene; alpha alpha alpha triplication) are quite frequent in the overall group of thalassemias. It is therefore important for the operators in the field of thalassemia diagnosis to possess exact knowledge of them especially in order to prevent thalassemia major.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234571

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  The epidemiology of abnormal hemoglobins in Mediterranean high-level athletes.

Authors:  Imed Touhami; Slaheddine Fattoum; Amina Bibi; Hajer Siala; Taieb Messaoud; Donia Koubaa; Rafik Mankai; Zakia Bartagi; Daniel Le Gallais
Journal:  Eur J Appl Physiol       Date:  2009-12-16       Impact factor: 3.078

2.  HbE Level and Red Cell Parameters in Heterozygous HbE With and Without α0-Thalassemia Trait.

Authors:  Sakorn Pornprasert; Monthathip Tookjai; Manoo Punyamung; Panida Pongpunyayuen
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-12       Impact factor: 0.900

3.  Erythrocyte reference values in Emirati people with and without α+ thalassemia.

Authors:  Srdjan Denic; Abdul-Kader Souid; Nicolaas Nagelkerke; Saad Showqi; Ghazala Balhaj
Journal:  BMC Blood Disord       Date:  2011-02-24

4.  Is RBC discrimination index suitable for differentiating between α- and β- thalassemias?

Authors:  Ajit C Gorakshakar; Roshan B Colah
Journal:  Indian J Hum Genet       Date:  2011-09

5.  Genotype-Phenotype Correlations of β-Thalassemia Mutations in an Azerbaijani Population.

Authors:  Chingiz Asadov; Eldar Abdulalimov; Tahira Mammadova; Surmaya Gafarova; Yegana Guliyeva; Gunay Aliyeva
Journal:  Turk J Haematol       Date:  2017-01-25       Impact factor: 1.831

6.  Hemoglobin A2 Lowered by Iron Deficiency and α -Thalassemia: Should Screening Recommendation for β -Thalassemia Change?

Authors:  Srdjan Denic; Mukesh M Agarwal; Bayan Al Dabbagh; Awad El Essa; Mohamed Takala; Saad Showqi; Javed Yassin
Journal:  ISRN Hematol       Date:  2013-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.